Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)

Silverberg JI, Bieber T, Eyerich K, Armstrong AW, Nickoloff BJ, Natalie CR, Gallo G, Okragly A, Wolf E, Xu C, Moser BA, Rueda MJ, Elmaraghy[...]

Wang Y, Sun B, Ma F, Tao B, Gu Y, Zhou Z, Kim J, Zhang L, Liu Z, Ten Hoeve J, Stiles L, Fernandez-Del-Rio L,[...]

Ma EJ, Roberts AM, Jeong CY, Chou P, Katz A, Nong Y, Johnsen N, Yan M, Ochoa MT, Armstrong AW. GLP-1RAs and cardiovascular risk reduction[...]